Activity

Filter

Cancel
Date Panel Item Activity
14 actions
Haematological malignancies cancer susceptibility v4.34 POT1 Arina Puzriakova Added comment: Comment on phenotypes: OMIM phenotypes (Tumor predisposition syndrome 3, OMIM:615848) accessed on 27-10-2025
Haematological malignancies cancer susceptibility v4.34 POT1 Arina Puzriakova Phenotypes for gene: POT1 were changed from Tumor predisposition syndrome 3, OMIM:615848; Lymphoid and myeloid cancers; Multiple myeloma to Tumor predisposition syndrome 3, OMIM:615848; Lymphoid and myeloid cancers; Multiple myeloma
Haematological malignancies cancer susceptibility v4.33 POT1 Arina Puzriakova Publications for gene: POT1 were set to PMID: 36467798; 30213928
Haematological malignancies cancer susceptibility v4.32 POT1 Arina Puzriakova edited their review of gene: POT1: Changed publications to: 27528712, 29693246, 33216348, 34193977, 34769003, 36467798, 39845416
Haematological malignancies cancer susceptibility v4.32 POT1 Arina Puzriakova changed review comment from: Germline variants in POT1 have been linked to a wide range of haematological malignancies including myeloid and lymphoid neoplasms (PMID: 27528712; 34193977; 34769003) and multiple myeloma (PMID: 36467798; 39845416). POT1 variants lead to telomeric elongation and increased telomere fragility as the main functional effect. However, haematologic malignancies often occur as part of a broader spectrum of POT1-associated cancers and therefore this gene will be flagged for additional GMS expert review to determine whether it is appropriate to include on this panel.; to: Germline variants in POT1 have been linked to a wide range of haematological malignancies including myeloid and lymphoid neoplasms (PMID: 27528712; 29693246; 33216348; 34193977; 34769003) and multiple myeloma (PMID: 36467798; 39845416). POT1 variants lead to telomeric elongation and increased telomere fragility as the main functional effect.
Haematological malignancies cancer susceptibility v4.32 POT1 Arina Puzriakova Classified gene: POT1 as Amber List (moderate evidence)
Haematological malignancies cancer susceptibility v4.32 POT1 Arina Puzriakova Added comment: Comment on list classification: Multiple studies have been published showing germline POT1 variants predispose to a broad spectrum of haematological cancers including chronic lymphocytic leukaemia, lymphomas and myeloid malignancies. Inclusion on this panel may be warranted to allow clinical surveillance of high-risk families.

However, haematologic malignancies often occur as part of a broader spectrum of POT1-associated cancers and therefore this gene will be flagged for additional GMS expert review to determine whether it is appropriate to include on this panel.
Haematological malignancies cancer susceptibility v4.32 POT1 Arina Puzriakova Gene: pot1 has been classified as Amber List (Moderate Evidence).
Haematological malignancies cancer susceptibility v4.31 POT1 Arina Puzriakova Phenotypes for gene: POT1 were changed from Multiple myeloma to Tumor predisposition syndrome 3, OMIM:615848; Lymphoid and myeloid cancers; Multiple myeloma
Haematological malignancies cancer susceptibility v4.30 POT1 Arina Puzriakova Tag Q3_25_promote_green tag was added to gene: POT1.
Tag Q3_25_expert_review tag was added to gene: POT1.
Haematological malignancies cancer susceptibility v4.30 POT1 Arina Puzriakova changed review comment from: Germline variants in POT1 have been linked to a wide range of haematological malignancies including myeloid and lymphoid neoplasms (PMID: 27528712; 34193977; 34769003) and multiple myeloma (PMID: 36467798; 39845416). POT1 variants lead to telomeric elongation and increased telomere fragility as the main functional effect. However, hematologic malignancies often occur as part of a broader spectrum of POT1-associated cancers and therefore this gene will be flagged for additional GMS expert review to determine whether it is appropriate to include on this panel.; to: Germline variants in POT1 have been linked to a wide range of haematological malignancies including myeloid and lymphoid neoplasms (PMID: 27528712; 34193977; 34769003) and multiple myeloma (PMID: 36467798; 39845416). POT1 variants lead to telomeric elongation and increased telomere fragility as the main functional effect. However, haematologic malignancies often occur as part of a broader spectrum of POT1-associated cancers and therefore this gene will be flagged for additional GMS expert review to determine whether it is appropriate to include on this panel.
Haematological malignancies cancer susceptibility v4.30 POT1 Arina Puzriakova reviewed gene: POT1: Rating: GREEN; Mode of pathogenicity: None; Publications: 27528712, 34193977, 34769003, 36467798, 39845416; Phenotypes: Tumor predisposition syndrome 3, OMIM:615848, Lymphoid and myeloid cancers, Multiple myeloma; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Haematological malignancies cancer susceptibility v4.4 POT1 Lauma Freimane reviewed gene: POT1: Rating: GREEN; Mode of pathogenicity: None; Publications: ; Phenotypes: ; Mode of inheritance: None
Haematological malignancies cancer susceptibility v4.4 POT1 Lauma Freimane gene: POT1 was added
gene: POT1 was added to Haematological malignancies cancer susceptibility. Sources: Expert Review
Mode of inheritance for gene: POT1 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Publications for gene: POT1 were set to PMID: 36467798; 30213928
Phenotypes for gene: POT1 were set to Multiple myeloma
Penetrance for gene: POT1 were set to unknown
gene: POT1 was marked as current diagnostic